JP2012512157A - 癌を治療するためのエンザスタウリン - Google Patents

癌を治療するためのエンザスタウリン Download PDF

Info

Publication number
JP2012512157A
JP2012512157A JP2011540796A JP2011540796A JP2012512157A JP 2012512157 A JP2012512157 A JP 2012512157A JP 2011540796 A JP2011540796 A JP 2011540796A JP 2011540796 A JP2011540796 A JP 2011540796A JP 2012512157 A JP2012512157 A JP 2012512157A
Authority
JP
Japan
Prior art keywords
cancer
patient
hdac2
enzastaurin
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011540796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012512157A5 (cg-RX-API-DMAC10.html
Inventor
ゴピナス・ガンジ
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2012512157A publication Critical patent/JP2012512157A/ja
Publication of JP2012512157A5 publication Critical patent/JP2012512157A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011540796A 2008-12-15 2009-12-07 癌を治療するためのエンザスタウリン Withdrawn JP2012512157A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12245108P 2008-12-15 2008-12-15
US61/122,451 2008-12-15
PCT/US2009/066925 WO2010074936A2 (en) 2008-12-15 2009-12-07 Enzastaurin for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2012512157A true JP2012512157A (ja) 2012-05-31
JP2012512157A5 JP2012512157A5 (cg-RX-API-DMAC10.html) 2012-08-23

Family

ID=41785627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540796A Withdrawn JP2012512157A (ja) 2008-12-15 2009-12-07 癌を治療するためのエンザスタウリン

Country Status (11)

Country Link
US (1) US20110288032A1 (cg-RX-API-DMAC10.html)
EP (1) EP2376081A2 (cg-RX-API-DMAC10.html)
JP (1) JP2012512157A (cg-RX-API-DMAC10.html)
KR (1) KR20110084533A (cg-RX-API-DMAC10.html)
CN (1) CN102245184A (cg-RX-API-DMAC10.html)
AU (1) AU2009330492A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0922367A2 (cg-RX-API-DMAC10.html)
CA (1) CA2746085A1 (cg-RX-API-DMAC10.html)
EA (1) EA201170821A1 (cg-RX-API-DMAC10.html)
MX (1) MX2011006433A (cg-RX-API-DMAC10.html)
WO (1) WO2010074936A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525118A (ja) * 2013-07-19 2016-08-22 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. がんの治療のためのpimキナーゼ阻害剤と組み合わせたペプチドエポキシケトンプロテアソーム阻害剤

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
WO2013112598A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal caner
WO2013112601A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
EP2814493A4 (en) * 2012-02-17 2015-07-22 Pharmacyclics Inc COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB, AND USES THEREOF
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
WO2020223657A1 (en) * 2019-05-02 2020-11-05 Predictive Technology Group, Inc. Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1449529B1 (en) 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US20080096923A1 (en) * 2004-07-23 2008-04-24 Aniz Girach Methods For Diagnosing And Treating Diabetic Microvascular Complications
US20090202659A1 (en) * 2005-06-10 2009-08-13 Gimble Jeffrey M Modulation of Peripheral Clocks in Adipose Tissue

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525118A (ja) * 2013-07-19 2016-08-22 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. がんの治療のためのpimキナーゼ阻害剤と組み合わせたペプチドエポキシケトンプロテアソーム阻害剤
JP2019189625A (ja) * 2013-07-19 2019-10-31 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. がんの治療のためのpimキナーゼ阻害剤と組み合わせたペプチドエポキシケトンプロテアソーム阻害剤

Also Published As

Publication number Publication date
AU2009330492A1 (en) 2010-07-01
CN102245184A (zh) 2011-11-16
KR20110084533A (ko) 2011-07-25
US20110288032A1 (en) 2011-11-24
CA2746085A1 (en) 2010-07-01
WO2010074936A2 (en) 2010-07-01
WO2010074936A3 (en) 2010-09-16
EP2376081A2 (en) 2011-10-19
MX2011006433A (es) 2011-07-19
EA201170821A1 (ru) 2011-12-30
BRPI0922367A2 (pt) 2016-05-24

Similar Documents

Publication Publication Date Title
Lissanu Deribe et al. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer
Gooding et al. The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers
Jeschke et al. Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors
Du et al. 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer
Agnihotri et al. Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients
Lu et al. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
Hsu et al. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer
Wang et al. LncRNA MALAT1 accelerates non‐small cell lung cancer progression via regulating miR‐185‐5p/MDM4 axis
Li et al. BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer
Asnaghi et al. Hypoxia promotes uveal melanoma invasion through enhanced Notch and MAPK activation
Sun et al. Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis
US20110288032A1 (en) Enzastaurin for the treatment of cancer
Zhang et al. LINE-1 retrotransposition promotes the development and progression of lung squamous cell carcinoma by disrupting the tumor-suppressor gene FGGY
Hou et al. The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer
Ullmann et al. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro
US20160038498A1 (en) Methods for the treatment of cancer
Gritti et al. DNAJB1-PRKACA fusion drives fibrolamellar liver cancer through impaired SIK signaling and CRTC2/p300-mediated transcriptional reprogramming
Ma et al. Increased chromosomal instability characterizes metastatic renal cell carcinoma
Yoshikawa et al. Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer
Sippl et al. MiRNA-181d expression significantly affects treatment responses to carmustine wafer implantation
KR101936210B1 (ko) 암 예후 예측용 바이오마커
Cheng et al. Suppression of FOXO1 activity by SIRT1-mediated deacetylation weakening the intratumoral androgen autocrine function in glioblastoma
Yang et al. Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2–breast cancer
Severson et al. Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients
KR101999476B1 (ko) Alk 저해제에 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 약물 선택의 정보 제공 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120706

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130614